Your browser doesn't support javascript.
loading
Overexpression of Cathepsin L is associated with gefitinib resistance in non-small cell lung cancer
Cui, F; Wang, W; Wu, D; He, X; Wu, J; Wang, M.
Affiliation
  • Cui, F; Southern Medical University. Nanfang Hospital. Department of Oncology. Guangzhou. China
  • Wang, W; Sun Yat-sen Memorial Hospital of Sun Yat-sen University. Department of Thoracic Surgery. Guangzhou. China
  • Wu, D; Sun Yat-sen Memorial Hospital of Sun Yat-sen University. Department of Thoracic Surgery. Guangzhou. China
  • He, X; Sun Yat-sen Memorial Hospital of Sun Yat-sen University. Department of Thoracic Surgery. Guangzhou. China
  • Wu, J; Sun Yat-sen Memorial Hospital of Sun Yat-sen University. Pharmaceutical Department. Guangzhou. China
  • Wang, M; Sun Yat-sen Memorial Hospital of Sun Yat-sen University. Department of Thoracic Surgery. Guangzhou. China
Clin. transl. oncol. (Print) ; Clin. transl. oncol. (Print);18(7): 722-727, jul. 2016. ilus, graf
Article in En | IBECS | ID: ibc-153498
Responsible library: ES1.1
Localization: BNCS
ABSTRACT
Lung cancer, the most common malignancy, is still the leading cause of cancer-related death worldwide. Non-small-cell lung cancer (NSCLC) accounts for 80 % of all lung cancers. Recent studies showed Cathepsin L (CTSL) is overexpressed in various cancerous tissues; however, the association between CTSL expression and EGFR-TKI resistance remains unknown. In this study, we investigated the expression of CTSL in lung cancer specimens and matched normal tissues by quantitative real-time PCR and IHC. The functional role of CTSL in resistant PC- 9/GR cell line was investigated by proliferation and apoptosis analysis compared with control PC-9 cells. Our results found that the level of CTSL expression was higher in NSCLC tissues compared with matched normal adjacent tissue samples, and CTSL was more highly expressed in PC-9/GR cells compared to PC-9 cells. Knocking-down of CTSL in PC-9/GR cells could decrease cell proliferation and potentiate apoptosis induced by gefitinib, suggesting CTSL may contribute to gefitinib resistance in NSCLC. CTSL might be explored as a candidate of therapeutic target for modulating EGFR-TKI sensitivity in NSCLC (AU)
RESUMEN
No disponible
Subject(s)
Search on Google
Collection: 06-national / ES Database: IBECS Main subject: Drug Resistance / Carcinoma, Non-Small-Cell Lung / Cathepsin L Type of study: Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: Clin. transl. oncol. (Print) Year: 2016 Document type: Article
Search on Google
Collection: 06-national / ES Database: IBECS Main subject: Drug Resistance / Carcinoma, Non-Small-Cell Lung / Cathepsin L Type of study: Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: Clin. transl. oncol. (Print) Year: 2016 Document type: Article